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y+LAT-1 and 4F2hc are the subunits of a transporter complex for cationic amino acids, located mainly in the basolateral plasma membrane of
epithelial cells in the small intestine and renal tubules. Mutations in y+LAT-1 impair the transport function of this complex and cause a selective
aminoaciduria, lysinuric protein intolerance (LPI, OMIM #222700), associated with severe, complex clinical symptoms. The subunits of an active
transporter co-localize in the plasma membrane, but the exact process of dimerization is unclear since direct evidence for the assembly of this
transporter in intact human cells has not been available. In this study, we used fluorescence resonance energy transfer (FRET) microscopy to
investigate the interactions of y+LAT-1 and 4F2hc in HEK293 cells expressing y+LAT-1 and 4F2hc fused with ECFP or EYFP. FRET was
quantified by measuring fluorescence intensity changes in the donor fluorophore (ECFP) after the photobleaching of the acceptor (EYFP).
Increased donor fluorescence could be detected throughout the cell, from the endoplasmic reticulum and Golgi complex to the plasma membrane.
Therefore, our data prove the interaction of y+LAT-1 and 4F2hc prior to the plasma membrane and thus provide evidence for 4F2hc functioning as
a chaperone in assisting the transport of y+LAT-1 to the plasma membrane.
© 2007 Elsevier B.V. All rights reserved.Keywords: y+LAT-1; 4F2hc; Heteromeric amino acid transporters; Protein–protein interaction; FRET1. Introduction
System y+L amino acid transporter 1 (y+LAT-1) and 4F2
heavy chain (4F2hc) are the two subunits of the heteromeric
amino acid transporter for cationic amino acids (CAAs). The
transporter is expressed in humans mainly in the epithelial cells
of the renal tubules and the brush border of the small intestine,
being located exclusively in the basolateral plasma membrane.⁎ Corresponding authors. M. Kleemola is to be contacted at Department of
Medical Genetics, University of Turku, Kiinamyllynkatu 10, 20520 Turku,
Finland. Tel.: +358 2 333 7456; fax: +358 2 333 7300. K.M. Heiskanen,
Department of Biology, Laboratory of Animal Physiology, University of Turku,
FIN-20014, Turku, Finland. Fax: +358 2 333 6598.
E-mail addresses: maaria.kleemola@utu.fi (M. Kleemola),
Kaisa.Heiskanen@btk.fi (K.M. Heiskanen).
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doi:10.1016/j.bbamem.2007.04.020To a smaller extent, it is also expressed in other tissues, namely
peripheral blood lymphocytes, the placenta and lungs, to
mention but a few. The y+LAT-1/4F2hc transporter complex
facilitates the y+L type amino acid transport by transferring
cationic amino acids, mainly lysine and arginine, from the cell
into the extra-cellular space independently of sodium, and
neutral amino acids back into the cell in a sodium-dependent
fashion [1–3].
The light subunit (LSHAT) of the complex, y+LAT-1, is the
product of gene SLC7A7 [4]. It is a membrane-spanning,
∼40 kDa protein with 12 putative transmembrane (TM) do-
mains, with both the N and C termini orientated to the
cytoplasm [5,6]. In the functioning holotransporter, y+LAT-1
defines the transporter's substrate specificity [7]. Mutations in
y+LAT-1 give rise to a severe selective aminoaciduria, ly-
sinuric protein intolerance (LPI, OMIM 222700), through an
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a total of 33 LPI-causing mutations have been described
worldwide [10–12], all causing similar dysfunction of the
holotransporter.
The heavy subunit (HSHAT) of this amino acid transporter
complex, 4F2hc (CD98), is a type II glycoprotein, with a
cytoplasmic N terminus and extracellular C terminus. It is an
∼85 kDa product of the SLC3A2 gene [13,14]. It is expressed
ubiquitously on the cell surface and was originally detected in
activated lymphocytes [15]. In addition to amino acid transport,
4F2hc participates in various other cellular functions, including
the differentiation, attachment and fusion of activated or
growing cells [1]. For example, it binds into integrins and
regulates their function, thus presumably influencing the
maintenance of cell polarity [16,17]. No mutations have been
discovered in 4F2hc, supporting the proposal that 4F2hc has
crucial functions in the cell and suggesting that mutations in
4F2hc are likely to be lethal to embryonic life [18,19].
Several studies have shown that y+LAT-1 and 4F2hc co-
localize in the basolateral plasma membrane [5,6]. Previous
studies have also revealed that the light chains cannot reach
the plasma membrane in the absence of 4F2hc [7]. These
findings suggest that 4F2hc assists in the insertion of y+LAT-1
into the plasma membrane, thereby ensuring the correct
expression location of the amino acid transporter. Evidence
for the interactions of y+LAT-1 and 4F2hc in the ER was
already discovered in earlier co-precipitation studies [5,6,20].
However, the assembly point of this amino acid transporter
complex and the mechanism by which 4F2hc regulates the
intracellular trafficking of y+LAT-1 through the protein-
modifying machinery to the final localization still remains
unresolved. Similarly, the intracellular location where y+LAT-1
and 4F2hc begin interacting has not been demonstrated in
intact cells. It seems also possible that the holotransporter
formed by y+LAT-1 and 4F2hc is not a dimer but a tetramer,
as has been suggested to be the case with another hetero-
dimeric amino acid transporter formed by rBAT and b0,+AT
[21,22].
In order to better understand the assembly of the y+LAT-1/
4F2hc transporter complex, we used fluorescence resonance
energy transfer (FRET) microscopy [23–25] to study the
heterodimerization of y+LAT-1 and 4F2hc and the intracellular
trafficking of the complex. Using the acceptor photobleaching
method [26] for measuring FRETwe were able to visualize, for
the first time, the physical interactions between y+LAT-1 and
4F2hc at the single-cell level. These interactions were observed
throughout the biosynthetic pathway, from the endoplasmic
reticulum and Golgi to the plasma membrane.
2. Materials and methods
2.1. The plasmid constructs
The hy+LAT-1 and h4F2hc cDNAs were cloned into four different
expression vectors (pEYFP-N1, pEYFP-C1, pECFP-N1 and pECFP-C1,
produced by Living Colors®, BD Biosciences Clontech, Palo Alto, CA) in
frame with two alternative fluorophores, EYFP or ECFP, flanking the
fluorophore either in the N or C terminus. The cDNA fragment of h4F2hcwas digested from pDsRed2-N1-4F2hc and pDsRed2-C1-4F2hc [26] with
restriction enzymes HindIII and SalI, and SalI and BamHI, respectively. The
cDNA fragments for hy+LAT-1 constructs were amplified with PCR using
primers (For ECFP/EYFP-C1-y+LAT-1 constructs the forward and reverse
primers in respective order were: 5′-CAAGCTTCCATGGTTGACAGCACT-
GAG-3′ and 5′-GTCGACGTT AGACTTGGGACCCGTTG-3′. The forward
and reverse primers for the ECFP/EYFP-N1-y+LAT-1 constructs were 5′-
GCAAGCTTATGGTTGACAGCACTGAG-3′ and 5′-CGCGTCGACAGTTA-
GACTTGGGATCCCGTTG-3′, respectively.) with HindIII/SalI or BamHI/SalI
digestion sites introduced flanking the cDNA, poly-A-tailed and subcloned into
pGEM®-T Easy vectors (pGEM®-T Easy Vector System I, Promega
Corporation, Madison, WI, USA). The fragments were cleaved from pGEM®-
T Easy plasmids and subsequently cloned into the pEYFP and pECFP vectors to
create eight different fluorescent fusion protein constructs.
2.2. Cell culture and transfection
Human Embryonal Kidney 293 cells (HEK293; ATCC #CRL-1573),
epithelial cells of renal origin, were cultured at 37 °C, in 5.1% CO2, in Eagle's
Minimum Essential Medium supplemented with FBS (10%), 1 mM L-
glutamine, 100 U/ml penicillin–streptomycin and 30 μg/ml gentamycine. For
transfection, the cells were grown on sterilised cover slips that were poly-L-
lysine-treated to prevent the detachment of cells during the fixing procedure.
The cells were transfected with y+LAT-1 fusion constructs alone, or together
with 4F2hc fusion constructs (ratio 1:1) using FuGENE 6 Transfection Reagent
(Roche Molecular Biochemicals, Mannheim, Germany) according to the
manufacturer's instructions, the reagent to DNA ratio being 3:1. 16 to 20 h
after the transfection, the cells were fixed with 4% paraformaldehyde in PBS for
30 min. The cover slips were mounted on the microscope slides using
Vectashield® Mounting Medium For Fluorescence H-100 (Vector Laboratories,
Burlingame, CA, USA), sealed using rubber cement and then kept protected
from light at +4 °C until imaged with confocal microscopy.
2.3. Dual imaging of ECFP and EYFP by confocal microscopy
The fluorescent fusion proteins were studied with a Zeiss LSM 510 META
confocal microscope (Carl Zeiss, Jena, Germany) with a 63× NA 1.4 plan
apochromat oil immersion objective. The argon laser lines, 458 and 514 nm,
were used for the excitation of ECFP and EYFP. Fluorescence emission, divided
by a 458/514 dichroic mirror, was collected through band pass filters of 480–
520 nm for ECFP and 535–590 nm for EYFP. The cross-talk between the two
channels was eradicated by using the multi track mode, in which the 458 and
514 nm laser lines scan images for ECFP (track 1) and EYFP (track 2)
sequentially line by line in two steps.
2.4. Live-cell experiments
For live-cell experiments, HEK-293 cells were cultured under the same
conditions mentioned above. The cells were plated on glass-bottomed Petri
dishes with a diameter of 3.5 cm (MatTeck Corporation, Ashland, MA, USA)
and double-transfected with ECFP-y+LAT-1 and EYFP-4F2hc 18 h prior to
confocal microscopy. For the imaging, the Petri dishes were mounted on the
microscope stage in a humified incubator with 5% CO2 atmosphere. The
temperature was maintained at 37 °C during the live-cell imaging. The confocal
microscope settings used are described in the paragraph above.
2.5. Acceptor photobleaching FRET microscopy
The cells were first visually studied to examine the localization of the
fluorescent fusion proteins in different combinations. After the correct
localization of the fusion proteins was verified in the cells, we proceeded to
studying the interactions of the transporter subunits by means of acceptor
photobleaching FRET microscopy [26]. In the study at whole-cell level (an
average of 10 cells per ECFP-EYFP construct combination was studied), we
photobleached EYFP by scanning a region of interest (ROI) 300 consecutive
times using the 514 nm line from the argon laser. Images from CFP and YFP
channels were collected before and after the photobleaching. The argon laser
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achieve the best dynamic range.
After the initial verification of FRET in the cells at the whole-cell level, the
cells with representative constructs (20 cells per construct combination) were re-
examined with the 2× zoom in order to define the location of protein–protein
interaction more accurately. Three parallel areas were chosen as the regions of
interest (ROIs) in which EYFP was photobleached by scanning the areas 75 or
100 consecutive times using the 514 nm line from the argon laser. The areas to
be photobleached were largely determined by the conformation of the cell, but
where possible we chose areas of the plasma membrane, ER and Golgi (in that
order, see Figs. 3a, 4a and 5a) to be examined. The ROIs used were squares of
uniform size.
2.6. The localization of fusion proteins in the endoplasmic reticulum
and the Golgi complex in fixed cells
The endoplasmic reticulum was visualized by staining double-transfected
HEK 293 cells grown on a cover slip using the SelectFX® Alexa Fluor® 488
Endoplasmic Reticulum Labeling Kit (Molecular Probes™, Invitrogen
Corporation, Carlsbad, CA, USA) according to the manufacturer's instructions.
The primary antibody in the kit detects the ER-associated protein disulphide
isomerase (PDI). In order to allow the simultaneous imaging of the fluorescent
CFP and YFP fusion proteins used, the secondary antibody provided by the kit
was replaced by the similar but spectrally more suitable Alexa Fluor® 633-dye-
labelled secondary antibody (Molecular Probes™).
The fluorescent fusion proteins were studied using the confocal microscope
mentioned above with a 63× NA 1.4 plan apochromat oil immersion objective.
The 405, 514 and 633 nm laser lines were used for the excitation of CFP, YFP
and the Alexa Fluor® 633 dye, respectively. As before, the images were obtained
in the multi track mode. On each channel, the imaging slice was adjusted to
0.07 μm. Fluorescence emission was collected through band pass filters of 435–
485 nm for ECFP and 535–590 nm for EYFP. For the Alexa Fluor® 633 dye, the
fluorescence emission was collected with a spectral metadetector from the range
of 647 to 711 nm.
The Golgi complex, however, was visualized by transfecting the cells with
the same commercial Golgi-targetted expression vector as used previously by
Toivonen and co-workers [27], pECFP-Golgi (Living Colors®, BD Biosciences
Clontech), in addition to the EYFP-C1-y+LAT-1 and/or EYFP-C1-4F2hc fusion
proteins. The fluorescent proteins were expressed for approximately 20 h post-
transfectionally before the cells were fixed with 4% paraformaldehyde. The cells
were imaged with the confocal microscope with the appropriate filters in the
fashion described above.
2.7. Mathematical calculations
The fluorescence intensities of ECFP and EYFP of the bleached and non-
bleached cells before and after bleaching were quantified with MetaMorph
computing software (Universal Imaging Corporation, Downingtown, PA, USA)
by measuring the change in the CFP fluorescence intensities. The change in the
fluorescence intensity between pre- and post-bleach values was calculated using
the formula modified from the article by Karpova and co-workers [25], EF=
(Iafter− Ibefore)×100 / Iafter. This formula yielded the FRET energy transfer
efficiency as a percentage. In order to be able to compare the EF values yielded
by different construct combinations, we also calculated the net fluorescence
increase value for each construct combination by subtracting the mean of the EF
values of the control regions from the mean of the EF values of the bleached
regions.Fig. 1. A schematic diagram of the y+LAT-1/4F2hc dimer in its hypothetical
conformation. The oblongs with the abbreviations CFP and YFP illustrate all the
potential locations for the fluorescent proteins in the eight different fusion
protein constructs created. The dimer image was adapted from Verrey et al.,
1999 [34], in which it was originally part of Fig. 2, p. 187. (©Springer-Verlag,
Berlin, Heidelberg. Reproduced with the kind permission of Dr. Verrey and
Springer Science and Business Media).3. Results
3.1. The localization of the fusion protein amino acid
transporter complex
The interactions of the two transporter complex subunits,
y+LAT-1 and 4F2hc, were investigated by means of the gene-ration of eight different fluorescent proteins by fusing the
subunits into the amino or carboxy terminus of ECFP or EYFP
vectors (for a schematic illustration, see Fig. 1). We observed
the fluorescent fusion proteins being transported normally along
the biosynthetic pathway into their proper locations in the
plasma membrane irrespective of the presence or location of the
fluorescent tag in either of the subunits. The results thus indicate
that the fluorescent proteins do not disturb the transport of
y+LAT-1 or 4F2hc in the cell (Fig. 2a). The most abundant
fluorescent signals were detected in the Golgi network and the
plasma membrane (Fig. 2b). The localization of the fusion
proteins was similar in both live and fixed cells (live-cell data
not shown).
In order to confirm the intracellular compartments in which
the fluorescent subunits co-localize, the ER and Golgi of
y+LAT-1-4F2hc-transfected cells were labelled with cell
organelle-specific labels: anti-PDI antibodies for the ER and
the Golgi-targetted ECFP vector for the Golgi complex. The
transporter subunits co-localized in both these cellular compart-
ments. Fig. 2b demonstrates the location of the ER (red in panel
a) and the Golgi complex (red in panel b) in HEK 293 cells. The
co-localization profiles illustrate the co-localization of y+LAT-1
(green, 4F2hc not shown) with the ER dye (red), and that of
y+LAT-1, 4F2hc (both green) and the Golgi-plasmid (red), in
panels c and d, respectively.
3.2. y+LAT-1 and 4F2hc interact in the ER, Golgi and plasma
membrane
In order to study the interaction of the subunits in different
intracellular compartments, we chose four different construct
Fig. 2. (a) Confocal microscope images of HEK 293 cells transfected with y+LAT-1-ECFP and EYFP-4F2hc. The distribution of the transfected fluorescent fusion
proteins closely resembles the correct localizations of native y+LAT-1 and 4F2hc. The fluorescent tags in the N terminus of 4F2hc or either end of y+LAT-1 thus do not
affect the intracellular trafficking of the transporter subunits. In this figure, the distribution of y+LAT-1 is displayed on the CFP channel and that of 4F2hc on the YFP
channel. The overlay image illustrates the co-localization of the transporter subunits in the Golgi complex (arrowheads) and plasma membrane (arrows). The white
arrows and the arrowheads indicate the plasma membrane and the Golgi complex, respectively. (b) The location of the ER and Golgi in HEK 293 cells. This figure
illustrates the localization of the ER and Golgi in cells transfected with y+LAT-1 and 4F2hc. (a) A confocal microscope image of HEK 293 cells double-transfected with
ECFP-y+LAT-1 (green) and EYFP-4F2hc (channel not shown), and stained with the ER-specific, anti-PDI primary antibody and Alexa Fluor 633 secondary antibody
(red) showing the localization of the ER (red). The white arrow depicts the line on which the co-localization of y+LAT-1 and the ER antibody was measured (the graph
shown in panel c). (b) A confocal microscope image of HEK 293 cells triple-transfected with EYFP-y+LAT-1, EYFP-4F2hc and the Golgi-targeted, ECFP vector. The
YFP fluorescence is shown in green, the CFP fluorescence in red. The white arrow depicts the line on which the co-localization of y+LAT-1 and 4F2hc (YFP), and the
Golgi-targeted plasmid was measured (shown in panel d) (c) The co-localization profile of the CFP fluorescence and the antibody signal in the cell presented in panel a,
demonstrating the localization of the y+LAT-1-4F2hc dimer in the ER. The CFP fluorescence is illustrated with a green line, the anti-PDI-Alexa Fluor 633 fluorescence
with a red line. The line on which the fluorescence intensities were measured in the cells is shown with a white arrow in panel a of this figure. (d) The co-localization
profile of the YFP and CFP fluorescence in the cells presented in panel b (white arrow), demonstrating the location of the y+LAT-1-4F2hc dimer with relation to the
Golgi complex. The YFP fluorescence is illustrated with a green line, CFP with a red line.
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initial FRET experiments at the whole-cell level (data not
shown). We chose the two double-transfectants with intracel-lular 4F2hc labels in which the donor brightening was the most
noticeable, (y+LAT-1-ECFP+EYFP-4F2hc and ECFP-y+LAT-
1+EYFP-4F2hc) and, for comparison, the corresponding con-
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ECFP+4F2hc-EYFP and ECFP-y+LAT-1+4F2hc-EYFP). The
FRET efficiencies were measured in the three photobleached
areas: the plasma membrane, ER and Golgi, in that order, when
visible in the cell. Fig. 3a shows an image of the HEK 293 cells
co-transfected with ECFP-y+LAT-1 and EYFP-4F2hc. In the
cells bearing these constructs, the photobleaching of EYFP
resulted in a considerable brightening of ECFP, thus indicating
interactions between y+LAT-1 and 4F2hc. These interactions
were visible throughout the ER, Golgi complex and plasma
membrane. The FRET efficiency values are presented as
numerical values in Table 1. The average FRET efficiency
values for bleached regions in construct combinations with an
N-terminal 4F2hc label were 16.9% for ECFP-y+LAT-1+Fig. 3. (a) Representative FRET images of HEK 293 cells co-transfected with E
from the CFP (left) and YFP (right) channels; the bottom row shows the res
intensity changes of the fluorophores during FRET microscopy (colour bar).
interest (illustrated by white squares), i.e. the plasma membrane (the left and r
the ECFP emission. This result suggests that in addition to interacting in the pla
complex. Note that the unbleached regions maintained consistent emission of
donor fluorescence increases in cells with ECFP-y+LAT-1 and EYFP-4F2hc. The
co-transfected with ECFP-y+LAT-1 and EYFP-4F2hc. Each cell studied is repre
three, which are dark-coloured, depict the fluorescence intensity increase in the
when possible. The five light-coloured bars (three for the first two cells) illustr
the cells; the first three of them in the same cell and the last two in an adjac
donor fluorescence was considerably increased in the bleached regions (dark bar
average 12.4% (Table 1).EYFP-4F2hc (n=48) and 15.2% for y+LAT-1-ECFP+EYFP-
4F2hc (n=39).
In order to confirm that the intensity increase of donor
fluorescence was indeed due to disruption of energy transfer
between fluorophores by acceptor photobleaching and not
caused by the imaging procedure, we also measured the donor
fluorescence intensity change in five different unbleached
regions (internal controls), three of them in the same cell as the
bleached areas, when possible, and two in a neighbouring cell.
As illustrated by Fig. 3b, the fluorescence intensity increase in
the unbleached, control regions (pale bars) was significantly
lower than in bleached regions (dark bars), thus indicating that
the imaging itself did not affect the FRET measurements. The
average donor fluorescence increase in the control regions inCFP-y+LAT-1 and EYFP-4F2hc. The top row shows the pre-bleach images
pective post-bleach images. The images are pseudo-coloured to show the
The photobleaching of EYFP with 514 nm laser light in the regions of
ight squares) and the Golgi (the middle square), resulted in brightening of
sma membrane, ECFP-y+LAT-1 and EYFP-4F2hc also interact in the Golgi
both fluorophores (plasma membrane, white arrows). (b) The post-bleach
bar chart illustrates the changes in donor fluorescence (EF values) in cells
sented by a group of eight bars (the first two cells by six bars). The first
three bleached ROIs, the plasma membrane, ER and Golgi, in that order,
ate the fluorescence intensity increase in the non-bleached, control areas in
ent cell. In the cells transfected with ECFP-y+LAT-1 and EYFP-4F2hc, the
s) compared to the control regions (pale bars) with the difference being on
Table 1
The mean of the EF values of the fluorescence intensity measurements per construct combination in the one-cell-focused study
Construct combinations Mean of intensity










intensity change b (%)
ECFP-y+LAT-1+EYFP-4F2hc 16.9±7.1 48 4.5±6.1 74 12.4
ECFP-y+LAT-1+4F2hc-EYFP 2.8±3.3 60 1.3±4.0 100 1.5
ECFP-y+LAT-1 1.9±2.8 60 2.3±2.9 100 −0.4
y+LAT-1-ECFP+EYFP-4F2hc 15.2±10.0 39 5.8±12.2 65 9.3
y+LAT-1-ECFP+4F2hc-EYFP 3.7±14.5 60 0.2±12.9 100 3.5
y+LAT-1-ECFP 1.1±5.8 42 1.9±2.8 70 −0.8
pECFP+pEYFP 7.6±9.2 45 3.7±8.9 75 3.8
a The mean intensity change was calculated as an average of the number of bleached or control regions indicated in the table. The numbers of bleached and control
areas per cell were 3 and 5, respectively.
b The net donor fluorescence intensity change was calculated by subtracting the mean of the EF values of the control regions from that of the bleached regions.
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y+LAT-1+EYFP-4F2hc (n=74) and 5.8% for y+LAT-1-ECFP+
EYFP-4F2hc (n=65). The net values for the donor fluores-Fig. 4. (a) Representative FRET images of HEK 293 cells co-transfected with ECFP-
CFP (left) and YFP (right) channels; the bottom row shows the respective post-bleac
fluorophores during FRET microscopy (colour bar). The elimination of the EYFP em
Golgi and plasma membrane) did not result in brightening of the ECFP emission in t
4F2hc prevents the fluorescence resonance energy transfer from occurring. (b) The p
EYFP. The bar chart displays the changes in the donor fluorescence intensity values (
FRET in these cells bearing the construct combinations with 4F2hc tagged in its C te
increase being under 10% and the average difference between the bleached and concence increase are therefore 12.4% for ECFP-y+LAT-1+
EYFP-4F2hc and 9.3% for y+LAT-1-ECFP+EYFP-4F2hc
(Table 1). The increase in donor fluorescence intensity seemedy+LAT-1 and 4F2hc-EYFP. The top row shows the pre-bleach pictures from the
h images. The images are pseudo-coloured to show the intensity changes of the
ission by the 514 nm laser light in the regions of interest (the white squares; the
he photobleached areas. The location of the fluorescent tag in the C terminus of
ost-bleach donor fluorescence increases in cells with ECFP-y+LAT-1 and 4F2hc-
EF values), the colour-coding being identical to that in Fig. 3. The inefficiency of
rminus is reflected by low EF values— the highest donor fluorescence intensity
trol regions being 1.5% (Table 1).
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on y+LAT-1.
3.3. The plasma membrane prevents FRET between the
transporter subunits
The results obtained from the measurements on cells co-
transfected with y+LAT-1, with either an N- or C-terminal label,
combined with C-terminally-labelled 4F2hc (ECFP-y+LAT-1+
4F2hc-EYFP and y+LAT-1-ECFP+4F2hc-EYFP) were remark-
ably different from those described above, which were obtained
from double-transfected cells with N-terminally-labelled 4F2hc
proteins. In the cells with C-terminally-labelled 4F2hc, photo-
bleaching of the acceptor fluorophore did not result in dequen-
ching of the donor, which indicates that when the fluoroproteinFig. 5. (a) Representative FRET images of HEK 293 cells transfected with ECFP-y+
(right) channels; the bottom row shows the respective post-bleach images. The imag
FRETmicroscopy (colour bar). Despite the lack of the acceptor in these cells, we expo
them for the presence of pseudo-fluorescence. The mere exposure of ECFP to 514 n
bleached areas depicted by white squares), thus proving that the donor fluorescence int
post-bleach donor fluorescence increases in cells with ECFP-y+LAT-1. The bar chart d
the legend, see Fig. 3. The fluorescence intensity in the cells transfected with ECFP-y+
following acceptor photobleaching. The increase in fluorescence intensity is thus insig
12.5%, but the average EF in the bleached regions was only 1.9%, with the differencis located in the extra-cellular C terminus of 4F2hc, FRET does
not occur (Fig. 4a). The low EF values displayed in Fig. 4b also
strengthen the hypothesis that the plasma membrane prevents
FRET between the donor and acceptor fluorophore. The
average EF values in photobleached areas were 2.8% for
ECFP-y+LAT-1+4F2hc-EYFP (n=60) and 3.7% for y+LAT-1-
ECFP+4F2hc-EYFP (n=60). The respective values for control
areas were 1.3% (n=100) and 0.2% (n=100). Thus, the net EF
values are 1.5% for ECFP-y+LAT-1+4F2hc-EYFP and 3.5%
for y+LAT-1-ECFP+4F2hc-EYFP (Table 1).
3.4. The negative controls
In order to determine the effect of laser light on the donor
fluorescence intensity, we transfected the cells with only ECFP-LAT-1. The top row shows the pre-bleach pictures from the CFP (left) and YFP
es are pseudo-coloured to show the intensity changes of the fluorophores during
sed the cells to 514 nm laser light similarly to the double-transfectants and tested
m light did not result in a significant brightening of the ECFP fluorescence (the
ensity increase observed in the double-transfectants was real and relevant. (b) The
isplays the changes in the donor fluorescence intensity values (EF) in detail— for
LAT-1 increased in the bleached regions in a manner similar to the control regions
nificant. The largest single increase in fluorescence intensity was approximately
e between the bleached and control regions being −0.4% (Table 1).
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fluorescence to exposure to 514 nm laser light in the absence of
the acceptor fluorophore. As demonstrated by Figs. 5a and b,
there was no significant increase in donor fluorescence intensity
in the absence of EYFP. The average EF values of the bleached
and control regions in cells with ECFP-y+LAT-1 were 1.9% and
2.3%, respectively. The corresponding values for cells with
y+LAT-1-ECFP were 1.1% and 1.9%. The net EF values were
−0.4% for ECFP-y+LAT-1 and −0.8% for y+LAT-1-ECFP
(Table 1). In addition, we measured FRET in cells transfected
with the empty ECFP and EYFP vectors. The donor
fluorescence intensity increase subsequent to acceptor photo-
bleaching, which can be considered a threshold value for true
FRET, remained fairly low. However, the net EF (3.8%) was
higher than that in the cells with C-terminally-labelled 4F2hc
(1.5% and 3.5%).
4. Discussion
In order to visualize intracellular distribution and hetero-
merization of the y+LAT-1/4F2hc complex in the HEK 293
cells, we tagged the N or C terminus of y+LAT-1 and 4F2hc
with ECFP or EYFP. Previous studies have demonstrated that
y+LAT-1 and 4F2hc co-localize in the plasma membrane to
form a heteromer, which is necessary for the physiological
function of this transporter [5,6]. However, the precise
mechanisms or the intracellular site for the assembly of this
complex have not yet been defined. Previously, Toivonen et al.
discovered that an EGFP tag did not alter the localization of the
y+LAT-1/4F2hc complex [27]. Similarly, our experiments
confirmed that all fusion protein combinations of the y+LAT-
1/4F2hc complex were successfully transported to the plasma
membrane, thereby indicating that the fusion into fluorescent
proteins had no impact on the intracellular trafficking of the
transporter subunits. Abundant signals of both of the fluor-
ophores were detected in the ER, Golgi and plasma membrane.
Therefore, based on these data, one can conclude that
fluorescent proteins can be used for investigating the intracel-
lular maturation and assembly of this protein complex.
To investigate the interactions of y+LAT-1 and 4F2hc, we
made measurements of fluorescence resonance energy transfer
(FRET) by confocal microscopy. In recent years, FRET micro-
scopy has become an increasingly popular tool for examining
the physical interactions of plasma membrane transporter sub-
units [28–31]. A clear benefit of the FRET method over the
classical biochemical methods, such as immunoprecipitation
and cross-linking, is the fact that it allows the detection of
protein complex subunit oligomerization in intact cells. There
are numerous different FRET techniques which are suitable for
the detection of protein–protein interactions inside the cells; in
this study, we opted for the acceptor photobleaching FRET
assay to visualize the heteromerization of y+LAT-1 and 4F2hc.
This method is based on the fact that laser light-induced selec-
tive photobleaching of the acceptor fluorophore results in an
increase in donor fluorescence.
In our study, FRETwas detected in cells when y+LAT-1, with
either one of its cytoplasmic termini tagged with ECFP orEYFP, was co-expressed with 4F2hc tagged in its intracellular N
terminus (Fig. 3b and Table 1). In contrast, if 4F2hc was tagged
in its extracellular, C terminus, the FRET efficiency values
produced were considerably lower (Fig. 4b and Table 1). FRET
is a quantum physical phenomenon which occurs between a
fluorescence donor and a fluorescence acceptor in close
proximity (1–10 nm) if the emission spectrum of the donor
fluorophore overlaps with the excitation spectrum of the
acceptor fluorophore and the fluorophores are orientated
correctly with regard to each other [23–25]. Our results indicate
that the distances between the intracellular termini of y+LAT-1
and 4F2hc fall within this range, thus fulfilling the criteria for
FRET. The fluorophore in the extracellular C terminus of
4F2hc, however, is separated from the intracellular y+LAT-1
tags by the plasma membrane. The thickness of the plasma
membrane is 4–10 nm [32,33], therefore, the distance alone
should not be too great for some FRET to occur. It would seem
more probable that it is complexity of the structure of the plasma
membrane that hinders and reduces the energy transfer between
the extracellular and intracellular domains of the transporter
subunits. Alternatively, the plasma membrane could be
preventing the energy transfer by altering the physical
orientation of the donor and the acceptor, thus rendering it
unfavourable for FRET. At this stage, we can only speculate on
the factors underlying the quenching effect of the plasma
membrane; further studies are required to establish the nature of
the interference.
To confirm the validity of the FRET data, we performed a
wide range of control experiments (Table 1). In each of the
FRET experiments, unbleached regions were used as internal
control areas to verify that the donor fluorescence values did, in
fact, increase due to acceptor photobleaching and were not
caused by the imaging process itself (e.g. by changes in the
focal plane). In addition, the FRET efficiency values (EF)
obtained from the construct combinations were compared to the
changes in ECFP emission values in the absence of the EYFP
acceptor and also those measured with empty vectors (Fig. 5b
and Table 1). These internal and external negative controls
provided a baseline for the FRET measurements and could
therefore be used as stringent control for true FRET. All these
negative controls yielded considerably lower EF values than
those obtained from the double-transfectants with the N-
terminal label in 4F2hc, thereby confirming that the co-
expression of y+LAT-1 and 4F2hc fusion proteins result in
FRET only as a consequence of heteromerization. We found
very little day-to-day variation in the EF values of any construct
combination, unlike Karpova and co-workers; the values in
bleached and non-bleached regions seemed to remain within the
same range regardless of the day. There was, however, a
noticeable degree of variation within the cells sharing the same
construct combination, perhaps depending on the fusion protein
expression levels.
There are two different hypotheses on how y+LAT-1 reaches
the plasma membrane to form the amino acid transporter with
4F2hc. According to one, the subunits are carried to the plasma
membrane individually and only multimerize in the plasma
membrane or in its immediate vicinity. This is, however,
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the heavy subunit, 4F2hc, the light subunit cannot be found in
the plasma membrane alone [7]. The other hypothesis stresses
the importance of 4F2hc and suggests that multimerization of
the subunits at some earlier point in the protein biosynthetic
pathway is required for transporting y+LAT-1 to the plasma
membrane. The previous co-precipitation studies have already
suggested interactions between the subunits at the ER [5,6]. The
results of the current study provide further evidence for the latter
hypothesis, as the interactions of y+LAT-1 and 4F2hc were not
restricted to the plasma membrane but took place considerably
earlier in the biosynthetic pathway, occurring all the way from
the ER through the Golgi to the plasma membrane. This result
supports the idea that 4F2hc functions as a chaperone assisting
y+LAT-1's transport to the plasma membrane.
In conclusion, the use of FRET microscopy for assessing the
interactions of y+LAT-1 and 4F2hc in individual cells provides a
reproducible and quantifiable method for studying the assembly
of the human y+LAT-1/4F2hc amino acid transporter. Since the
efforts to produce an antibody against human y+LAT-1 have so
far been unsuccessful, FRET microscopy offers an important
alternative tool for investigating the biochemical mechanisms
involved in the formation of this complex. Knowledge of the
mechanisms that dictate the interactions and intracellular
distribution of the y+LAT-1/4F2hc complex is fundamental for
understanding the molecular basis of LPI. Our future interest is
to define the key molecular elements that determine the
relationship of y+LAT-1 and 4F2hc and turn them into a fully
functioning amino acid transporter complex. Further work is
still required in order to establish the effect of the different
y+LAT-1 mutations on the interactions between the transporter
subunits.
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